Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Patient outcomes within schizophrenia treatment: a look at the role of long-acting injectable antipsychotics.

Bera RB.

J Clin Psychiatry. 2014;75 Suppl 2:30-3. doi: 10.4088/JCP.13065su1c.07. Review.

2.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
3.
4.

[Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature].

Graffino M, Montemagni C, Mingrone C, Rocca P.

Riv Psichiatr. 2014 May-Jun;49(3):115-23. doi: 10.1708/1551.16905. Review. Italian.

PMID:
25000887
5.

[Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].

Misdrahi D, Delgado A, Bouju S, Comet D, Chiariny JF.

Encephale. 2013 May;39 Suppl 1:S8-14. doi: 10.1016/j.encep.2012.03.005. Epub 2013 Mar 28. French.

PMID:
23541914
6.

Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics.

Heres S, Lambert M, Vauth R.

Eur Psychiatry. 2014 Nov;29 Suppl 2:1409-13. doi: 10.1016/S0924-9338(14)70001-X. Epub 2014 Nov 22. Review.

7.

Long-acting Injectable Antipsychotics in First-episode Schizophrenia.

Jeong HG, Lee MS.

Clin Psychopharmacol Neurosci. 2013 Apr;11(1):1-6. doi: 10.9758/cpn.2013.11.1.1. Epub 2013 Apr 24.

8.
9.
10.

Efficacy and safety of long acting injectable atypical antipsychotics: a review.

De Berardis D, Marini S, Carano A, Lang AP, Cavuto M, Piersanti M, Fornaro M, Perna G, Valchera A, Mazza M, Iasevoli F, Martinotti G, Di Giannantonio M.

Curr Clin Pharmacol. 2013 Aug;8(3):256-64. Review.

PMID:
23343445
11.

Long-acting injectable antipsychotics: evidence of effectiveness and use.

Manchanda R, Chue P, Malla A, Tibbo P, Roy MA, Williams R, Iyer S, Lutgens D, Banks N.

Can J Psychiatry. 2013 May;58(5 Suppl 1):5S-13S. Review.

PMID:
23945067
13.

Long-acting injectable antipsychotics in the elderly: guidelines for effective use.

Masand PS, Gupta S.

Drugs Aging. 2003;20(15):1099-110. Review.

PMID:
14651433
14.

Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.

Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU.

J Clin Psychiatry. 2013 Oct;74(10):957-65. doi: 10.4088/JCP.13r08440.

PMID:
24229745
15.
16.

Rethinking the role of long-acting atypical antipsychotics in the community setting.

Altamura AC, Aguglia E, Bassi M, Bogetto F, Cappellari L, De Giorgi S, Fagiolini A, Ferrannini L, Girardi P.

Int Clin Psychopharmacol. 2012 Nov;27(6):336-49. Review.

PMID:
22859065
17.

Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.

Rossi G, Frediani S, Rossi R, Rossi A.

BMC Psychiatry. 2012 Aug 21;12:122. doi: 10.1186/1471-244X-12-122. Review.

18.

A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives.

Iyer S, Banks N, Roy MA, Tibbo P, Williams R, Manchanda R, Chue P, Malla A.

Can J Psychiatry. 2013 May;58(5 Suppl 1):14S-22S.

PMID:
23945063
19.

A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.

Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM.

J Clin Psychiatry. 2009 Oct;70(10):1397-406. doi: 10.4088/JCP.09m05284yel.

PMID:
19906343
20.
Items per page

Supplemental Content

Write to the Help Desk